



## Fractyl Health to Present Scientific Updates on Revita® and Rejuva® Programs at Upcoming Medical Congresses

May 2, 2023

LEXINGTON, Mass.—([BUSINESS WIRE](#))— Fractyl Health, a commercial-stage, organ-editing metabolic therapeutics company focused on pioneering new approaches to the treatment of type 2 diabetes (T2D), announced today that it will be presenting updates on its Revita® and Rejuva® programs at several upcoming medical congresses in May 2023.

Fractyl Health will present two posters (in person and virtually) at Digestive Disease Week (DDW) from May 6-9, 2023, in Chicago, IL. The first poster presentation, “Duodenal Mucosal Resurfacing Procedure Training and Implementation,” abstract number Mo1895, will be presented on May 8, 2023, from 12:30-1:30 pm CDT. The second poster presentation, “Initial Feasibility and Safety of a Novel Endoscopic Ultrasound-Guided Local Delivery System for AAV-Based Pancreatic Gene Therapy,” abstract number Mo1453, will be presented on May 8, 2023, at 12:30 – 1:30 pm CDT.

In addition, the Company will be presenting an oral presentation on Rejuva at the Keystone Symposium “Understanding Its Early Drivers and the Road to Therapeutics” from May 1-4, 2023, in Palm Springs, CA. The oral presentation, “AAV-mediated Gene Therapy for Improving Beta-cell Function,” will discuss the Company’s innovative screening techniques for determining metabolically active gene therapy candidates for the pancreas.

“We are excited to share our latest developments in the Revita® and Rejuva® programs with the scientific and medical community at these upcoming conferences,” said Dr. Harith Rajagopalan, CEO of Fractyl Health. “Our goal is to improve the lives of millions of people living with metabolic diseases, and these presentations will showcase the significant progress we are making towards achieving that goal with our Revita and Rejuva platforms.”

### About Fractyl Health

Fractyl Health is focused on pioneering new approaches to the treatment of T2D. Despite advances in treatment over the last 50 years, metabolic diseases in general, and T2D, in particular, continue to be a principal and rapidly growing driver of morbidity and mortality in the 21st century. Fractyl Health’s goal is to transform T2D treatment from chronic blood glucose management to disease-modifying therapies that target the organ-level root causes of the disease. Fractyl Health is a private organ-editing metabolic therapeutics company based in Lexington, MA. For more information, visit [www.fractyl.com](http://www.fractyl.com) or [www.twitter.com/FractylHealth](https://www.twitter.com/FractylHealth)

### About Revita®

Fractyl Health’s lead product candidate, Revita®, is based on the company’s insights surrounding the potential role of the gut in metabolic diseases. Revita is designed to remodel the duodenal lining via hydrothermal ablation (i.e., duodenal mucosal resurfacing) to edit abnormal intestinal nutrient sensing and signaling mechanisms that are a potential root cause of metabolic diseases. Revita has received a CE mark in Europe and, in January 2022, received reimbursement authorization through NUB in Germany. In the United States, Revita is for investigational use only under US law.

### About Rejuva®

Fractyl Health’s Rejuva® platform focuses on developing next-generation adeno-associated virus (AAV)-based, locally delivered gene therapies for the treatment of T2D and other metabolic diseases. The Rejuva platform is in preclinical development and has not yet been evaluated by regulatory agencies for investigational or commercial use. Rejuva leverages advanced delivery systems and proprietary screening methods to identify and develop metabolically active gene therapy candidates targeting the pancreas. The program aims to transform the management of metabolic diseases by offering novel, disease-modifying therapies that address the underlying root causes of disease.

### About DDW

Digestive Disease Week® (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW is an in-person and virtual meeting from May 6-9, 2023. The meeting showcases more than 3,100 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. More information can be found at [www.ddw.org](http://www.ddw.org).

## **About Keystone Symposium**

Keystone Symposia serves as a catalyst for the advancement of life-science research and medicine by convening the world's leading researchers, clinicians, global health experts and other biomedical players to discuss and solve today's greatest biomedical challenges. The internationally acclaimed conference series accelerates discovery, drives innovation and opens new frontiers in science and medicine, by catalyzing cross-disciplinary collaborations that generate novel approaches, technologies and applications.

## **Contacts**

Corporate Contact

Lisa Davidson, Chief Financial Officer

Lisa@fractyl.com, 781.902.8800

Media Contact Beth Brett, Corporate Communications

Bbrett@fractyl.com, 720.656.6544